{"drugs":["Nalbuphine Hydrochloride","Nubain"],"mono":{"0":{"id":"390630-s-0","title":"Generic Names","mono":"Nalbuphine Hydrochloride"},"1":{"id":"390630-s-1","title":"Dosing and Indications","sub":{"0":{"id":"390630-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>General anesthesia; Adjunct:<\/b> induction, 0.3-3 mg\/kg IV over 10-15 min<\/li><li><b>General anesthesia; Adjunct:<\/b> maintenance, 0.25-0.5 mg\/kg in single IV administrations, as needed<\/li><li><b>Pain (Moderate to Severe):<\/b> 10 mg subQ, IM or IV for a 70 kg individual repeated every 3 to 6 hours as needed; MAX single dose is 20 mg\/dose; MAX total daily dose is 160 mg\/day<\/li><li><b>Pain (Moderate to Severe), Including preoperative, postoperative, and obstetrical analgesia:<\/b> 10 mg subQ, IM or IV for a 70 kg individual repeated every 3 to 6 hours as needed; MAX single dose is 20 mg\/dose;  MAX total daily dose is 160 mg\/day<\/li><li><b>Shivering, Postanesthesia:<\/b> 0.08 mg\/kg IV<\/li><\/ul>"},"1":{"id":"390630-s-1-5","title":"Pediatric Dosing","mono":"safety and effectiveness not established in patients under 18 years of age"},"3":{"id":"390630-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>General anesthesia; Adjunct<\/li><li>Pain (Moderate to Severe)<\/li><li>Pain (Moderate to Severe), Including preoperative, postoperative, and obstetrical analgesia<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Opioid analgesic adverse reaction - Respiratory depression<\/li><li>Pruritus of skin<\/li><li>Shivering, Postanesthesia<\/li><li>Sickle cell anemia with crisis<\/li><\/ul>"}}},"3":{"id":"390630-s-3","title":"Contraindications\/Warnings","sub":[{"id":"390630-s-3-9","title":"Contraindications","mono":"hypersensitivity to nalbuphine or to any component of the product <br\/>"},{"id":"390630-s-3-10","title":"Precautions","mono":"<ul><li>biliary tract surgery; spasm of the sphincter of Oddi may occur<\/li><li>bradycardia has been reported in patients who did not receive atropine preoperatively<\/li><li>concomitant use of central nervous system depressants including alcohol, general anesthetics, hypnotics, opioid analgesics, phenothiazines, sedatives, or tranquilizers<\/li><li>emotionally unstable patients; monitoring recommended with prolonged use<\/li><li>head injury; respiratory depression or increases in cerebrospinal fluid pressure may be exaggerated; may obscure clinical course of injury<\/li><li>hepatic impairment; dose reduction recommended<\/li><li>intracranial lesion or preexisting increase in intracranial pressure; respiratory depression or increases in cerebrospinal fluid pressure may be exaggerated<\/li><li>myocardial infarction with nausea or vomiting<\/li><li>opioid abuse; monitoring recommended with prolonged use<\/li><li>renal impairment; dose reduction recommended<\/li><li>respiration impairment (eg, due to bronchial asthma, cyanosis, respiratory obstructions, concomitant medications, severe infection, uremia); increased risk respiratory depression; lower doses advised; reversible by naloxone<\/li><\/ul>"},{"id":"390630-s-3-11","title":"Pregnancy Category","mono":"Nalbuphine: B (FDA)<br\/>"},{"id":"390630-s-3-12","title":"Breast Feeding","mono":"Nalbuphine: Micromedex: Infant risk is minimal.<br\/>"}]},"4":{"id":"390630-s-4","title":"Drug Interactions","sub":[{"id":"390630-s-4-13","title":"Contraindicated","mono":"<ul>Naltrexone (probable)<\/ul>"},{"id":"390630-s-4-14","title":"Major","mono":"<ul><li>Alfentanil (probable)<\/li><li>Alphaprodine (probable)<\/li><li>Carbinoxamine (theoretical)<\/li><li>Codeine (probable)<\/li><li>Dihydrocodeine (probable)<\/li><li>Donepezil (theoretical)<\/li><li>Fentanyl (theoretical)<\/li><li>Fospropofol (theoretical)<\/li><li>Hydrocodone (probable)<\/li><li>Hydromorphone (probable)<\/li><li>Levorphanol (probable)<\/li><li>Meclizine (theoretical)<\/li><li>Meperidine (probable)<\/li><li>Methadone (probable)<\/li><li>Morphine (probable)<\/li><li>Morphine Sulfate Liposome (probable)<\/li><li>Oxycodone (probable)<\/li><li>Oxymorphone (probable)<\/li><li>Propoxyphene (probable)<\/li><li>Sufentanil (probable)<\/li><li>Suvorexant (theoretical)<\/li><li>Tapentadol (theoretical)<\/li><\/ul>"},{"id":"390630-s-4-15","title":"Moderate","mono":"<ul>Perampanel (probable)<\/ul>"}]},"5":{"id":"390630-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Diaphoresis (up to 9%)<\/li><li><b>Gastrointestinal:<\/b>Nausea and vomiting (6%), Xerostomia (4%)<\/li><li><b>Neurologic:<\/b>Dizziness (up to 5%), Headache (3%), Sedated (36%), Vertigo (up to 5%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Immunologic:<\/b>Hypersensitivity reaction (1% or less)<\/li><li><b>Neurologic:<\/b>Loss of consciousness, Seizure<\/li><li><b>Respiratory:<\/b>Pulmonary edema, Respiratory depression (1% or less)<\/li><\/ul>"},"6":{"id":"390630-s-6","title":"Drug Name Info","sub":{"0":{"id":"390630-s-6-17","title":"US Trade Names","mono":"Nubain<br\/>"},"2":{"id":"390630-s-6-19","title":"Class","mono":"<ul><li>Analgesic<\/li><li>Opioid<\/li><li>Opioid Agonist\/Antagonist<\/li><\/ul>"},"3":{"id":"390630-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"390630-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"390630-s-7","title":"Mechanism Of Action","mono":"Nalbuphine hydrochloride is a phenanthrene opioid analgesic with binding affinity to mu, kappa, and delta receptors with no affinity to sigma receptors, but acts primarily as a kappa agonist\/partial mu antagonist.<br\/>"},"8":{"id":"390630-s-8","title":"Pharmacokinetics","sub":{"2":{"id":"390630-s-8-25","title":"Metabolism","mono":"Hepatic <br\/>"},"3":{"id":"390630-s-8-26","title":"Excretion","mono":"Renal <br\/>"},"4":{"id":"390630-s-8-27","title":"Elimination Half Life","mono":"5 h <br\/>"}}},"10":{"id":"390630-s-10","title":"Monitoring","mono":"<ul><li>pain reduction, improvement in ability to move<\/li><li>mental and respiratory status<\/li><li>bowel movements<\/li><li>signs and symptoms of withdrawal<\/li><\/ul>"},"11":{"id":"390630-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/>Injection Solution: 10 MG\/ML, 20 MG\/ML<br\/><\/li><li><b>Amerinet Choice Nalbuphine Hydrochloride<\/b><br\/>Injection Solution: 10 MG\/ML, 20 MG\/ML<br\/><\/li><li><b>Novaplus Nalbuphine Hydrochloride<\/b><br\/>Injection Solution: 10 MG\/ML, 20 MG\/ML<br\/><\/li><li><b>Nubain<\/b><br\/>Injection Solution: 10 MG\/ML, 20 MG\/ML<br\/><\/li><\/ul>"},"13":{"id":"390630-s-13","title":"Clinical Teaching","mono":"<ul><li>Patient should avoid activities requiring mental alertness or coordination until drug effects are realized, as drug may cause dizziness or sedation.<\/li><li>This drug may cause sweating, constipation, nausea, or vomiting.<\/li><li>Patient should report depression.<\/li><li>Advise patient against sudden discontinuation of drug, as this may cause narcotic withdrawal symptoms, especially in patients on chronic therapy.<\/li><li>If self-administered, teach patient proper technique and placement of injections.<\/li><li>Advise patient to rotate injection sites.<\/li><li>Patient should not use alcohol or other CNS depressants while taking this drug.<\/li><\/ul>"}}}